Skip to main content

According to the results of a study published in the Lancet, treatment with Sutent® (sunitinib) was linked with the development of heart problems in some patients with metastatic gastrointestinal stromal tumors.

Sutent is an oral targeted agent that works by inhibiting multiple biologic pathways involved in the growth, replication, and spread of cancer cells. It deprives cancer cells of blood and nutrients needed for growth. Sutent has been shown to improve progression-free survival among patients with metastatic renal cell cancer as well as patients with metastatic gastrointestinal stromal tumors (GIST).[[1]]( "_ednref1")[[2]]( "_ednref2")

The possibility of Sutent-related heart problems has been raised by previous studies. To provide more detailed information about the heart effects of Sutent, researchers evaluated 75 patients with Gleevec® (imatinib)-resistant, metastatic GIST.[[3]]( "_ednref3") The patients had been enrolled in a Phase I/II clinical trial of Sutent.

The primary cardiovascular events of interest were cardiac death, myocardial infarction, and congestive heart failure. The study also assessed left ventricular ejection fraction (LVEF; a measure of heart function) and blood pressure.

  • Of the 75 patients, one died of a cardiovascular cause, one had a myocardial infarction, and six experienced congestive heart failure. Overall, 11% of patients experienced one of these cardiovascular outcomes.
  • LVEF fell below the normal range in 20% of patients.
  • 47% of patients developed high blood pressure.
  • Cardiovascular problems were more common among patients with a history of coronary artery disease than among patients without such a history.
  • In most cases the cardiovascular problems that arose could be medically managed.

The researchers conclude: “Patients treated with sunitinib should be closely monitored for hypertension and LVEF reduction, especially those with a history of coronary artery disease or cardiac risk factors.” They note: “Close monitoring could be a prudent approach until large studies can clearly define the nature and rate of sunitinib-associated cardiovascular adverse effects, especially in patients with cardiac risk factors, or history of coronary artery disease, or both.”

Patients who are being treated with Sutent may wish to discuss these results with their physician.

Recommended Articles

Image placeholder title

Screening - Prevention & Early Detection of Lung Cancer

Who is at risk of developing lung cancer? New lung cancer screening guidelines updated - July 2020.

Image placeholder title

How Should Oligometastatic NSCLC be Treated?

Local ablative treatment combined with immunotherapy improves long term survival in oligometastatic NSCLC.


[[1]]( "_edn1") Motzer R, Hutson T, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New EnglandJournal of Medicine. 2007; 356:115-124.

[[2]]( "_edn2") Demetri G, van Oosterom A, Garrett C, et al. Efficacy and Safety of Sunitinib with Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: A Randomised Controlled Trial. The Lancet. 2006;368:1329-38.

[[3]]( "_edn3") Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011-19.

Related News:Sutent® Improves Outcomes for Patients with GIST (10/11/2006)

Copyright Sarcoma Information Center on

Copyright © 2018 CancerConnect. All Rights Reserved.